Loading...
Keywords
Last Name
Institution

Entinostat: A Promising Treatment Option for Refractory and Recurrent Ewing Sarcoma Patients


Collapse Biography 

Collapse Overview 
Collapse abstract
Test both in vitro and in vivo the efficacy of Entinostat in combination with i) current salvage chemotherapeutics for Ewing Sarcoma and ii) with the PARP inhibitor to identify a novel management approach for patients with refractory or recurrent Ewing Sarcoma.

Collapse Time 
Collapse start date
2020-10-01
Collapse end date
2022-09-20